{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T05:11:27Z","timestamp":1794978687429,"version":"4.9.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s11523-023-00989-z","type":"journal-article","created":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T09:06:00Z","timestamp":1694768760000},"page":"667-684","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Population Pharmacokinetics and Exposure\u2013Response with Teclistamab in Patients With Relapsed\/Refractory Multiple Myeloma: Results From MajesTEC-1"],"prefix":"10.1007","volume":"18","author":[{"given":"Xin","family":"Miao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liviawati S.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun Xin Wang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Iwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Kobos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Stephenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristy","family":"Kemmerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa M.","family":"Uhlar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnob","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna D.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Trancucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Apte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raluca","family":"Verona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachit","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Hickey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaming","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Ouellet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh N.","family":"Samtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred L.","family":"Garfall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad Z.","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzette","family":"Girgis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,15]]},"reference":[{"issue":"5","key":"989_CR1","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.25791","volume":"95","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(5):548\u201367.","journal-title":"Am J Hematol"},{"issue":"2","key":"989_CR2","volume":"5","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Hemasphere. 2021;5(2):e528.","journal-title":"Hemasphere."},{"issue":"5","key":"989_CR3","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","volume":"36","author":"MV Mateos","year":"2022","unstructured":"Mateos MV, Weisel K, De Stefano V, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma. Leukemia. 2022;36(5):1371\u20136.","journal-title":"Leukemia"},{"key":"989_CR4","unstructured":"EMA summary of product characteristics. Abecma (idecabtagene vicleucel). Vol. 2022."},{"key":"989_CR5","unstructured":"EMA summary of product characteristics. CARVYKTI (ciltacabtagene autoleucel). Vol. 2022."},{"key":"989_CR6","unstructured":"EMA summary of product characteristics. TECVAYLI (teclistamab). Vol. 2022."},{"key":"989_CR7","unstructured":"US FDA. ABECMA\u00ae (idecabtagene vicleucel). Vol. 2022."},{"key":"989_CR8","unstructured":"US FDA. CARVYKTI\u2122 (ciltacabtagene autoleucel). Vol. 2022."},{"key":"989_CR9","unstructured":"US FDA prescribing information. TECVAYLI\u2122 (teclistamab). Vol. 2022."},{"issue":"10297","key":"989_CR10","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398(10297):314\u201324.","journal-title":"Lancet"},{"issue":"8","key":"989_CR11","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u201316.","journal-title":"N Engl J Med"},{"issue":"4","key":"989_CR12","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","volume":"34","author":"N Shah","year":"2020","unstructured":"Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34(4):985\u20131005.","journal-title":"Leukemia"},{"issue":"2","key":"989_CR13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21(2):207\u201321.","journal-title":"Lancet Oncol"},{"issue":"18","key":"989_CR14","doi-asserted-by":"publisher","first-page":"4538","DOI":"10.1182\/bloodadvances.2020002393","volume":"4","author":"K Pillarisetti","year":"2020","unstructured":"Pillarisetti K, Powers G, Luistro L, et al. Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv. 2020;4(18):4538\u201349.","journal-title":"Blood Adv"},{"issue":"10301","key":"989_CR15","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","volume":"398","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, Garfall AL, van de Donk N, et al. Teclistamab, a B-cell maturation antigen \u00d7 CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021;398(10301):665\u201374.","journal-title":"Lancet"},{"issue":"6","key":"989_CR16","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk N, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495\u2013505.","journal-title":"N Engl J Med"},{"issue":"18","key":"989_CR17","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","volume":"117","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691\u20135.","journal-title":"Blood"},{"issue":"5","key":"989_CR18","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/BF01061469","volume":"20","author":"JW Mandema","year":"1992","unstructured":"Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic\u2013pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm. 1992;20(5):511\u201328.","journal-title":"J Pharmacokinet Biopharm."},{"key":"989_CR19","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s40495-017-0090-5","volume":"3","author":"Y Chen","year":"2017","unstructured":"Chen Y, Xu Y. Pharmacokinetics of bispecific antibody. Curr Pharmacol Rep. 2017;3:126\u201337.","journal-title":"Curr Pharmacol Rep"},{"issue":"8","key":"989_CR20","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","volume":"49","author":"RJ Keizer","year":"2010","unstructured":"Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(8):493\u2013507.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"989_CR21","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2165\/11535960-000000000-00000","volume":"49","author":"NL Dirks","year":"2010","unstructured":"Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(10):633\u201359.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"989_CR22","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/jcph.1582","volume":"60","author":"Y Xu","year":"2020","unstructured":"Xu Y, Hu C, Chen Y, et al. Population pharmacokinetics and exposure-response modeling analyses of ustekinumab in adults with moderately to severely active ulcerative colitis. J Clin Pharmacol. 2020;60(7):889\u2013902.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"989_CR23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. Aaps J. 2011;13(2):143\u201351.","journal-title":"Aaps J"},{"key":"989_CR24","unstructured":"Beal SL, Boeckmann AJ, Bauer RJ. NONMEM 7.3.0 Users Guides. Vol. 2022. Ellicott City, MD: Icon Development Solutions; 1989-2015."},{"key":"989_CR25","unstructured":"The R Project for Statistical Computing. Vol. 2022."},{"issue":"10","key":"989_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2014.42","volume":"3","author":"E Gibiansky","year":"2014","unstructured":"Gibiansky E, Gibiansky L, Carlile DJ, Jamois C, Buchheit V, Frey N. Population pharmacokinetics of obinutuzumab (GA101) in chronic lymphocytic leukemia (CLL) and non-Hodgkin\u2019s lymphoma and exposure-response in CLL. CPT Pharmacometr Syst Pharmacol. 2014;3(10):e144.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"3","key":"989_CR27","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10928-018-9614-9","volume":"46","author":"M Garrett","year":"2019","unstructured":"Garrett M, Ruiz-Garcia A, Parivar K, Hee B, Boni J. Population pharmacokinetics of inotuzumab ozogamicin in relapsed\/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma. J Pharmacokinet Pharmacodyn. 2019;46(3):211\u201322.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"6","key":"989_CR28","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/cpt.665","volume":"102","author":"JFM Jacobs","year":"2017","unstructured":"Jacobs JFM, Mould DR. The role of FcRn in the pharmacokinetics of biologics in patients with multiple myeloma. Clin Pharmacol Ther. 2017;102(6):903\u20134.","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"989_CR29","doi-asserted-by":"publisher","first-page":"4595","DOI":"10.4049\/jimmunol.1403014","volume":"194","author":"M Pyzik","year":"2015","unstructured":"Pyzik M, Rath T, Lencer WI, Baker K, Blumberg RS. FcRn: the architect behind the immune and nonimmune functions of IgG and albumin. J Immunol. 2015;194(10):4595\u2013603.","journal-title":"J Immunol"},{"issue":"23","key":"989_CR30","doi-asserted-by":"publisher","first-page":"4222","DOI":"10.1182\/blood.V126.23.4222.4222","volume":"126","author":"X Yan","year":"2015","unstructured":"Yan X, Clemens PL, Puchalski T, et al. Target-mediated drug disposition of daratumumab following intravenous infusion in relapsed or refractory multiple myeloma after prior proteasome inhibitors and immunomodulatory drugs: a population pharmacokinetic analysis. Blood. 2015;126(23):4222.","journal-title":"Blood"},{"issue":"6","key":"989_CR31","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s40262-023-01240-8","volume":"62","author":"K Kim","year":"2023","unstructured":"Kim K, Phelps MA. Clinical pharmacokinetics and pharmacodynamics of daratumumab. Clin Pharmacokinet. 2023;62(6):789\u2013806.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"989_CR32","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1002\/cpt.779","volume":"102","author":"XS Xu","year":"2017","unstructured":"Xu XS, Schecter JM, Jansson R, Yan X. Response to \u201cThe role of FcRn in the pharmacokinetics of biologics in patients with multiple myeloma.\u201d Clin Pharmacol Ther. 2017;102(6):905.","journal-title":"Clin Pharmacol Ther"},{"key":"989_CR33","unstructured":"Gibiansky L, Gibiansky E. The relationship between target-mediated drug disposition (TMDD) and models with time-dependent clearance. Increasing drug development success: understanding drug-disease interactions through quantitative systems pharmacology. Vol. 2022: QuantPharm LLC; 2015."},{"issue":"1","key":"989_CR34","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/psp4.12143","volume":"6","author":"G Bajaj","year":"2017","unstructured":"Bajaj G, Wang X, Agrawal S, Gupta M, Roy A, Feng Y. Model-based population pharmacokinetic analysis of nivolumab in patients with solid tumors. CPT Pharmacometr Syst Pharmacol. 2017;6(1):58\u201366.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"12","key":"989_CR35","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1002\/psp4.12476","volume":"8","author":"J Zhang","year":"2019","unstructured":"Zhang J, Sanghavi K, Shen J, et al. Population pharmacokinetics of nivolumab in combination with ipilimumab in patients with advanced malignancies. CPT Pharmacometr Syst Pharmacol. 2019;8(12):962\u201370.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"6","key":"989_CR36","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1002\/cpt.1953","volume":"108","author":"HI Dai","year":"2020","unstructured":"Dai HI, Vugmeyster Y, Mangal N. Characterizing exposure-response relationship for therapeutic monoclonal antibodies in immuno-oncology and beyond: challenges, perspectives, and prospects. Clin Pharmacol Ther. 2020;108(6):1156\u201370.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"989_CR37","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1111\/bcp.14662","volume":"87","author":"S Kawakatsu","year":"2021","unstructured":"Kawakatsu S, Bruno R, K\u00e5gedal M, et al. Confounding factors in exposure-response analyses and mitigation strategies for monoclonal antibodies in oncology. Br J Clin Pharmacol. 2021;87(6):2493\u2013501.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"989_CR38","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1002\/cpt.656","volume":"101","author":"C Liu","year":"2017","unstructured":"Liu C, Yu J, Li H, et al. Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis. Clin Pharmacol Ther. 2017;101(5):657\u201366.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"989_CR39","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.it.2015.02.008","volume":"36","author":"KE Pauken","year":"2015","unstructured":"Pauken KE, Wherry EJ. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 2015;36(4):265\u201376.","journal-title":"Trends Immunol"},{"issue":"15","key":"989_CR40","doi-asserted-by":"publisher","first-page":"8047","DOI":"10.1200\/JCO.2021.39.15_suppl.8047","volume":"39","author":"S Girgis","year":"2021","unstructured":"Girgis S, Wang Lin SX, Pillarisetti K, et al. Teclistamab and talquetamab modulate levels of soluble B-cell maturation antigen in patients with relapsed and\/or refractory multiple myeloma. J Clin Oncol. 2021;39(15_Suppl):8047\u20138047.","journal-title":"J Clin Oncol"},{"issue":"4","key":"989_CR41","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1182\/bloodadvances.2022007625","volume":"7","author":"S Girgis","year":"2023","unstructured":"Girgis S, Wang Lin SX, Pillarisetti K, et al. Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed\/refractory multiple myeloma. Blood Adv. 2023;7(4):644\u20138.","journal-title":"Blood Adv"},{"issue":"3","key":"989_CR42","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/cts.13197","volume":"15","author":"Y Chen","year":"2022","unstructured":"Chen Y, Miao X, Hsu CH, et al. Population pharmacokinetics and exposure-response modeling analyses of guselkumab in patients with psoriatic arthritis. Clin Transl Sci. 2022;15(3):749\u201360.","journal-title":"Clin Transl Sci"},{"issue":"16 suppl","key":"989_CR43","doi-asserted-by":"publisher","first-page":"8034","DOI":"10.1200\/JCO.2023.41.16_suppl.8034","volume":"41","author":"SZ Usmani","year":"2023","unstructured":"Usmani SZ, Karlin L, Benboubker L, et al. Durability of responses with biweekly dosing of teclistamab in patients with relapsed\/refractory multiple myeloma achieving a clinical response in the MajesTEC-1 study. J Clin Oncol. 2023;41(16 suppl):8034.","journal-title":"J Clin Oncol"},{"issue":"16 suppl","key":"989_CR44","doi-asserted-by":"publisher","first-page":"8011","DOI":"10.1200\/JCO.2023.41.16_suppl.8011","volume":"41","author":"NWCJ van de Donk","year":"2023","unstructured":"van de Donk NWCJ, Moreau P, Garfall AL, et al. Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) \u00d7 CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2023;41(16 suppl):8011.","journal-title":"J Clin Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-023-00989-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-023-00989-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-023-00989-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T09:18:25Z","timestamp":1695460705000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-023-00989-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["989"],"URL":"https:\/\/doi.org\/10.1007\/s11523-023-00989-z","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"8 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Janssen Research & Development, LLC.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Xin Miao, Liviawati S. Wu, Yuki Iwaki, Rachel Kobos, Tara Stephenson, Kristy Kemmerer, Clarissa M. Uhlar, Arnob Banerjee, Danielle Trancucci, Amit Apte, Raluca Verona, Lixia Pei, Rachit Desai, Kathleen Hickey, Yaming Su, Daniele Ouellet, Mahesh Samtani, and Yue Guo are employees of Janssen. Shun Xin Wang Lin is an employee of LinkiDose Medicine Co., Ltd. Yan Xu is an employee of Simcere Pharmaceuticals. Yang Chen is an employee of Daiichi Sankyo. Jenna D. Goldberg is an employee of Vividon and holds stock in Janssen. Alfred L. Garfall is a consultant for Janssen, GSK, and Amgen; has received research funding from Janssen, Novartis, Tmunity, and CRISPR Therapeutics; and is an independent data monitoring committee member for Janssen. Amrita Krishnan is a consultant for Adaptive, Janssen, Sanofi, BMS, Pfizer, and Regneron; is a current equity holder in BMS; has received research funding from Janssen; is a Speakers\u2019 Bureau member for Takeda, GSK, and BMS; and is a member of the Board of Directors or advisory committee for Sutro. Saad Z. Usmani has served in a consulting or advisory role for Celgene, Amgen, Janssen, Takeda, GlaxoSmithKline, Karyopharm Therapeutics, AbbVie, Merck, Genentech, Gilead Sciences, and Bristol-Myers Squibb\/Celgene; and has received research funding from Celgene, Array BioPharma, Janssen, Pharmacyclics, Sanofi, Bristol-Myers Squibb, Amgen, Seattle Genetics, Merck, Skyline Diagnostics, and GlaxoSmithKline. Honghui Zhou is an employee of Jazz Pharmaceuticals and owns stocks in Jazz Pharmaceuticals and Johnson & Johnson. Suzette Girgis is an employee of Jazz Pharmaceuticals and holds stocks in JNJ and BMS.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at . Although these data are not currently publicly available for sharing, requests for sharing can be sent to the Corresponding Author and will be evaluated on an individual basis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Each study site\u2019s local independent ethics committee or institutional review board approved the study protocol. The study was conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines. All patients provided written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}